Coastal Endocrine Specialty Hospitals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 10-12-2024
- Paid Up Capital ₹ 2.10 M
as on 10-12-2024
- Company Age 12 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -17.05%
(FY 2022)
- Profit -57.58%
(FY 2022)
- Ebitda 1.33%
(FY 2022)
- Net Worth 4.98%
(FY 2022)
- Total Assets 1.16%
(FY 2022)
About Coastal Endocrine Specialty Hospitals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kongara Srikanth and Kongara Swapnika serve as directors at the Company.
- CIN/LLPIN
U85110AP2012PTC081838
- Company No.
081838
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jul 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Krishna, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Coastal Endocrine Specialty Hospitals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kongara Srikanth  | Director | 06-Jul-2012 | Current |
| Kongara Swapnika | Director | 09-Sep-2018 | Current |
Financial Performance of Coastal Endocrine Specialty Hospitals.
Coastal Endocrine Specialty Hospitals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 17.05% decrease. The company also saw a substantial fall in profitability, with a 57.58% decrease in profit. The company's net worth moved up by a moderate rise of 4.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Coastal Endocrine Specialty Hospitals?
In 2022, Coastal Endocrine Specialty Hospitals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Konacc Diagnostics Private LimitedActive 16 years 4 monthsKongara Srikanth and Kongara Swapnika are mutual person
- Endolife Speciality Hospitals Private LimitedActive 11 years 6 months
Kongara Srikanth and Kongara Swapnika are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Coastal Endocrine Specialty Hospitals?
Unlock and access historical data on people associated with Coastal Endocrine Specialty Hospitals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Coastal Endocrine Specialty Hospitals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Coastal Endocrine Specialty Hospitals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
